A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF - An innovative protocol for the treatment of metastatic melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 3, 1998, Pages 155-164

  Schachter, J ^a   Rakowsky, E ^b   Sulkes, A ^b   Adler, A ^b  

^a Robin Medical Center   (Israel)

^b NONE

Author keywords

Chemo biotherapy; GM CSF; Interferon ; Interleukin 2; Metastatic Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT ALPHA INTERFERON; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATIENT CODING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031875868     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.155     Document Type: Article

References (24)

1. Anaise D, Steinitz R, Ben Hur N. Solar radiation: A possible etiological factor in malignant melanoma in Israel. A retrospective study (1960-1972). Cancer 1978; 42:299-304
2. Cancer facts and figures - 1995. American Cancer Society, Inc, Atlanta, GA, 1995
3. Balch CM, Houghton A, Peters L. Cutaneous melanoma. In: De Vita VT, Helman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia: Lippincott, 1989; 1499-1542.
4. Del Prete SA, Maurer CH, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, decarbazin and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68:1403-1405.
5. McClay EF, Mastrangelo MJ. Systemic chemotherapy for melanoma. Semin Oncol 1988; 15:569-577.
6. McClay EF, McClay TM. Systemic chemotherapy for the treatment of metastatic melanoma. Sem Oncol 1996; 23:744-753.
7. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18(suppl 7):83-89.
8. Boyer CM, Dawson DV, Neal SE, et al. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res 1989; 49:2928-2934.
9. Hamilton JA. A colony-stimulating factor network involving mononuclear phagocytes and other cells. In: Van Furth (ed). Hematopoietic Growth Factors. Karger, 1992; 28-35.
10. Kurzrock R, Talpaz M, Gomez J, et al. Differential dose-related haematological effects of GM-CSF in pancytopema: evidence supporting the advantage of low over high-dose administration in selected patients. Br J Haematol 1991; 78:352-358.
11. Shimizu J, Suda T, Yoshioka T, et al. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen presenting cells. J Immunol 1989; 142:1053-1059.
12. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10:2338-2343.
13. Khayat D, Borel C, Yourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993; 11:2173-2180.
14. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol 1996; 7:827-835.
15. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
16. Schultz M, Poo WJ, Buzaid AC. A phase II study of cisplatin, dacarbazine, carmustine, tamoxifen and interfeion-α2B (IFN-α) in metastatic melanoma. Proc Am Soc Clin Oncol 1993; 12:390 (abstract).
17. Pyronen J, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10:1919-1926.
18. Stark JJ, Schulof R, Wiemann M, et al. alpha-interferon and chemohormonal therapy in advanced melanoma. A phase I-II NBSG/MAOP study. Proc Am Soc Clin Oncol 1993; 12:292 (abstract).
19. Adler A, Schachter J, Barenholz Y, et al. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients. Clinical and immunobiological effects. Cancer Biotherapy 1995; 10:293-305.
20. Ryan L, Kramer A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71:2995-3005.
21. Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992; 127:1303-1308.
22. Legha SS. Role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997; 24(suppl 4):24-31.
23. Philip PA, Flaherty L. Treatment of malignant melanoma with IL-2. Semin Oncol 1997, 24(suppl 4):32-38.
24. Keilholz V, Scheibenbogen C, Sommer M et al. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res 1996; 6:173-178.